Fibrinolytic-Facilitated Chronic Subdural Hematoma Drainage—A Systematic Review

Author(s):  
Yip Mang O ◽  
Shek Long Tsang ◽  
Gilberto Ka-Kit Leung
2021 ◽  
Vol 43 ◽  
pp. 101307
Author(s):  
Seungwon Kwon ◽  
Chul Jin ◽  
Minho Chung ◽  
JiEun Lee ◽  
Seung-Yeon Cho ◽  
...  

2021 ◽  
pp. neurintsurg-2021-017352
Author(s):  
Natasha Ironside ◽  
Candice Nguyen ◽  
Quan Do ◽  
Beatrice Ugiliweneza ◽  
Ching-Jen Chen ◽  
...  

Middle meningeal artery (MMA) embolization has been proposed as a minimally invasive treatment for chronic subdural hematoma (cSDH). The aim of this systematic review and meta-analysis is to compare outcomes after MMA embolization versus conventional management for cSDH. We performed a systematic review of PubMed, Embase, Oxford Journal, Cochrane, and Google Scholar databases from April 1987 to October 2020 in accordance with PRISMA guidelines. Studies reporting outcomes after MMA embolization for ≥3 patients with cSDH were included. A meta-analysis comparing MMA embolization with conventional management was performed. The analysis comprised 20 studies with 1416 patients, including 718 and 698 patients in the MMA embolization and conventional management cohorts, respectively. The pooled recurrence, surgical rescue, and in-hospital complication rates in the MMA embolization cohort were 4.8% (95% CI 3.2% to 6.5%), 4.4% (2.8% to 5.9%), and 1.7% (0.8% to 2.6%), respectively. The pooled recurrence, surgical rescue, and in-hospital complication rates in the conventional management cohort were 21.5% (0.6% to 42.4%), 16.4% (5.9% to 27.0%), and 4.9% (2.8% to 7.1%), respectively. Compared with conservative management, MMA embolization was associated with lower rates of cSDH recurrence (OR=0.15 (95% CI 0.03 to 0.75), p=0.02) and surgical rescue (OR=0.21 (0.07 to 0.58), p=0.003). In-hospital complication rates were comparable between the two cohorts (OR=0.78 (0.34 to 1.76), p=0.55). MMA embolization is a promising minimally invasive therapy that may reduce the need for surgical intervention in appropriately selected patients with cSDH. Additional prospective studies are warranted to determine the long-term durability of MMA embolization, refine eligibility criteria, and establish this endovascular approach as a viable definitive treatment for cSDH.


2019 ◽  
Vol 186 ◽  
pp. 105464 ◽  
Author(s):  
Jordan Court ◽  
Charles J Touchette ◽  
Christian Iorio-Morin ◽  
Harrison J. Westwick ◽  
François Belzile ◽  
...  

2018 ◽  
Vol 109 ◽  
pp. e792-e799 ◽  
Author(s):  
Kevin Phan ◽  
David Abi-Hanna ◽  
Jack Kerferd ◽  
Victor M. Lu ◽  
Adam A. Dmytriw ◽  
...  

2020 ◽  
Vol 49 (4) ◽  
pp. E7
Author(s):  
Alba Scerrati ◽  
Jacopo Visani ◽  
Luca Ricciardi ◽  
Flavia Dones ◽  
Oriela Rustemi ◽  
...  

OBJECTIVEChronic subdural hematoma (CSDH) is one of the most common neurosurgical pathologies, typically affecting the elderly. Its incidence is expected to grow along with the aging population. Surgical drainage represents the treatment of choice; however, postoperative complications and the rate of recurrence are not negligible. For this reason, nonsurgical alternatives (such as middle meningeal artery embolization, steroids, or tranexamic acid administration) are gaining popularity worldwide and need to be carefully evaluated, especially in the elderly population.METHODSThe authors performed a systematic review according to PRISMA criteria of the studies analyzing the nonsurgical strategies for CSDHs. They collected all papers in the English language published between 1990 and 2019 by searching different medical databases. The chosen keywords were “chronic subdural hematoma,” “conservative treatment/management,” “pharmacological treatment,” “non-surgical,” “tranexamic acid,” “dexamethasone,” “corticosteroid,” “glucocorticoid,” “middle meningeal artery,” “endovascular treatment,” and “embolization.”RESULTSThe authors ultimately collected 15 articles regarding the pharmacological management of CSDHs matching the criteria, and 14 papers included the endovascular treatment.CONCLUSIONSThe results showed that surgery still represents the mainstay in cases of symptomatic patients with large CSDHs; however, adjuvant and alternative therapies can be effective and safe in a carefully selected population. Their inclusion in new guidelines is advisable.


Sign in / Sign up

Export Citation Format

Share Document